8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 10, 2022)

Filed January 10, 2022For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report on January 10, 2022, providing preliminary financial results for the fourth quarter and full year 2021. The company announced that its key products, ONPATTRO®, GIVLAARI®, and OXLUMO®, generated approximately $199 million in global net product revenues for the fourth quarter of 2021 and a substantial $662 million for the full year 2021. This indicates strong commercial momentum for its approved therapies. Furthermore, Alnylam reported a robust preliminary cash position of approximately $2.4 billion as of December 31, 2021. This healthy balance sheet provides the company with significant financial flexibility to fund its ongoing research, development, and commercialization efforts for its pipeline of RNAi therapeutics. Investors should note that these figures are preliminary and unaudited, with complete financial results expected in February 2022.

Key Highlights

  • 1Preliminary Q4 2021 global net product revenues for ONPATTRO, GIVLAARI, and OXLUMO reached approximately $199 million.
  • 2Full year 2021 global net product revenues for these key products totaled approximately $662 million.
  • 3The company ended 2021 with a preliminary cash, cash equivalents, and marketable securities balance of approximately $2.4 billion.
  • 4The reported figures are unaudited and subject to adjustments pending the full financial results announcement in February 2022.
  • 5This filing primarily serves to provide early updates on product revenue and cash position.

Frequently Asked Questions

Alnylam reported preliminary global net product revenues of approximately $199 million for the fourth quarter of 2021 and approximately $662 million for the full year 2021, combining ONPATTRO®, GIVLAARI®, and OXLUMO®.

As of December 31, 2021, Alnylam had a preliminary cash, cash equivalents, and marketable securities balance of approximately $2.4 billion.

No, these are preliminary and unaudited financial results. The company expects to announce its complete and audited financial results for the fourth quarter and full year 2021 in February 2022.

This filing is primarily an update on product revenue performance and the company's cash position, providing investors with early insight into the company's commercial success and financial health ahead of the full earnings release.